JP2013500726A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013500726A5 JP2013500726A5 JP2012523129A JP2012523129A JP2013500726A5 JP 2013500726 A5 JP2013500726 A5 JP 2013500726A5 JP 2012523129 A JP2012523129 A JP 2012523129A JP 2012523129 A JP2012523129 A JP 2012523129A JP 2013500726 A5 JP2013500726 A5 JP 2013500726A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- poly
- complex
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102200147804 rs193929360 Human genes 0.000 claims 88
- 102220486434 Exocyst complex component 3-like protein_R338A_mutation Human genes 0.000 claims 70
- 102220561376 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT5_T87K_mutation Human genes 0.000 claims 26
- 102220612041 Lysozyme C_D85H_mutation Human genes 0.000 claims 26
- 102220152923 rs553059467 Human genes 0.000 claims 25
- 229920001184 polypeptide Polymers 0.000 claims 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 102220102849 rs187906987 Human genes 0.000 claims 23
- 102220561377 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT5_T87I_mutation Human genes 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 238000006467 substitution reaction Methods 0.000 claims 12
- 102200017883 rs864309687 Human genes 0.000 claims 11
- 102100022641 Coagulation factor IX Human genes 0.000 claims 6
- 108010076282 Factor IX Proteins 0.000 claims 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 6
- 229960004222 factor ix Drugs 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 6
- 102220330185 rs1364834319 Human genes 0.000 claims 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 5
- 230000013595 glycosylation Effects 0.000 claims 5
- 238000006206 glycosylation reaction Methods 0.000 claims 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 3
- 239000003054 catalyst Substances 0.000 claims 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 3
- -1 poly (alkylene glycol Chemical compound 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- 230000021615 conjugation Effects 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229920001451 polypropylene glycol Polymers 0.000 claims 2
- XLPJNCYCZORXHG-UHFFFAOYSA-N 1-morpholin-4-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCOCC1 XLPJNCYCZORXHG-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 102220508364 E3 ubiquitin-protein ligase XIAP_V86E_mutation Human genes 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 102220586243 Fructose-1,6-bisphosphatase isozyme 2_V86L_mutation Human genes 0.000 claims 1
- 102220493592 HLA class II histocompatibility antigen, DR beta 3 chain_V86D_mutation Human genes 0.000 claims 1
- 102220493565 HLA class II histocompatibility antigen, DR beta 3 chain_V86S_mutation Human genes 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229920001389 Poly(hydroxyalkylmethacrylamide) Polymers 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229940061720 alpha hydroxy acid Drugs 0.000 claims 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 238000010668 complexation reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 208000009429 hemophilia B Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 229920000765 poly(2-oxazolines) Polymers 0.000 claims 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 1
- 229920001390 poly(hydroxyalkylmethacrylate) Polymers 0.000 claims 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 102200068596 rs121918289 Human genes 0.000 claims 1
- 102220104694 rs149412531 Human genes 0.000 claims 1
- 102200133007 rs1805128 Human genes 0.000 claims 1
- 102200147803 rs193929360 Human genes 0.000 claims 1
- 125000005629 sialic acid group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23055109P | 2009-07-31 | 2009-07-31 | |
| US61/230,551 | 2009-07-31 | ||
| PCT/US2010/044177 WO2011014890A1 (en) | 2009-07-31 | 2010-08-02 | Modified factor ix polypeptides and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013500726A JP2013500726A (ja) | 2013-01-10 |
| JP2013500726A5 true JP2013500726A5 (enExample) | 2013-09-12 |
Family
ID=43529743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012523129A Pending JP2013500726A (ja) | 2009-07-31 | 2010-08-02 | 改変第ｉｘ因子ポリペプチドおよびその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20120164130A1 (enExample) |
| EP (1) | EP2461821A4 (enExample) |
| JP (1) | JP2013500726A (enExample) |
| KR (1) | KR20120060209A (enExample) |
| CN (1) | CN102573890A (enExample) |
| AU (1) | AU2010278721A1 (enExample) |
| BR (1) | BR112012002072A2 (enExample) |
| CA (1) | CA2769258A1 (enExample) |
| CL (1) | CL2012000238A1 (enExample) |
| CR (1) | CR20120052A (enExample) |
| CU (3) | CU20120018A7 (enExample) |
| DO (1) | DOP2012000030A (enExample) |
| EA (1) | EA201290069A1 (enExample) |
| EC (1) | ECSP12011637A (enExample) |
| GT (1) | GT201200023A (enExample) |
| IN (1) | IN2012DN00908A (enExample) |
| MX (1) | MX2012001346A (enExample) |
| PE (1) | PE20121643A1 (enExample) |
| SG (1) | SG178119A1 (enExample) |
| WO (1) | WO2011014890A1 (enExample) |
| ZA (1) | ZA201200716B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0720282B8 (pt) | 2006-12-15 | 2021-05-25 | Baxalta GmbH | construção proteica, composição farmacêutica, e, kit |
| SI3581650T1 (sl) | 2008-09-15 | 2023-06-30 | uniQuore biopharma B.V. | Polipeptidni mutant faktorja IX, njegova uporaba in metoda za njegovo proizvodnjo |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| EP3081233B1 (en) | 2009-07-27 | 2020-12-23 | Baxalta GmbH | Glycopolysialylation of proteins other than blood coagulation proteins |
| EP2459224B1 (en) | 2009-07-27 | 2016-06-01 | Baxalta GmbH | Blood coagulation protein conjugates |
| RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
| WO2012016131A1 (en) * | 2010-07-30 | 2012-02-02 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| HUE049352T2 (hu) | 2010-12-22 | 2020-09-28 | Baxalta GmbH | Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására |
| DK2794665T3 (da) * | 2011-12-19 | 2018-01-29 | Dilafor Ab | Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf |
| ES2744903T3 (es) * | 2012-11-20 | 2020-02-26 | Univ North Carolina Chapel Hill | Métodos y composiciones para proteínas del factor IX modificadas |
| WO2014165189A2 (en) | 2013-03-13 | 2014-10-09 | Eli Lilly And Company | Modified canine leptin polypeptides |
| TW201519900A (zh) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法 |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| BR112018002150A2 (pt) | 2015-08-03 | 2018-09-18 | Bioverativ Therapeutics Inc | proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas |
| CN109789181A (zh) | 2016-07-27 | 2019-05-21 | 费城儿童医院 | 用于调节因子ix功能的组合物和方法 |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| US12214023B2 (en) | 2018-10-18 | 2025-02-04 | Intellia Therapeutics, Inc. | Compositions and methods for expressing factor IX |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002086091A2 (en) * | 2001-04-25 | 2002-10-31 | The Regents Of The University Of California | Method to treat hemophilia by hepatic gene transfer of factor viii/ix with vesicle vector |
| US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| AU2004296860B2 (en) * | 2003-12-03 | 2010-04-22 | Novo Nordisk A/S | Glycopegylated factor IX |
| US8383388B2 (en) * | 2006-06-19 | 2013-02-26 | Catalyst Biosciences, Inc. | Modified coagulation factor IX polypeptides and use thereof for treatment |
| US7700734B2 (en) * | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
-
2010
- 2010-08-02 EA EA201290069A patent/EA201290069A1/ru unknown
- 2010-08-02 WO PCT/US2010/044177 patent/WO2011014890A1/en not_active Ceased
- 2010-08-02 JP JP2012523129A patent/JP2013500726A/ja active Pending
- 2010-08-02 PE PE2012000114A patent/PE20121643A1/es not_active Application Discontinuation
- 2010-08-02 MX MX2012001346A patent/MX2012001346A/es not_active Application Discontinuation
- 2010-08-02 IN IN908DEN2012 patent/IN2012DN00908A/en unknown
- 2010-08-02 BR BR112012002072A patent/BR112012002072A2/pt not_active IP Right Cessation
- 2010-08-02 CN CN2010800431356A patent/CN102573890A/zh active Pending
- 2010-08-02 US US13/388,288 patent/US20120164130A1/en not_active Abandoned
- 2010-08-02 CA CA2769258A patent/CA2769258A1/en not_active Abandoned
- 2010-08-02 SG SG2012005757A patent/SG178119A1/en unknown
- 2010-08-02 AU AU2010278721A patent/AU2010278721A1/en not_active Abandoned
- 2010-08-02 KR KR1020127005191A patent/KR20120060209A/ko not_active Withdrawn
- 2010-08-02 EP EP10805185.5A patent/EP2461821A4/en not_active Withdrawn
-
2012
- 2012-01-27 DO DO2012000030A patent/DOP2012000030A/es unknown
- 2012-01-30 EC EC2012011637A patent/ECSP12011637A/es unknown
- 2012-01-30 GT GT201200023A patent/GT201200023A/es unknown
- 2012-01-30 CU CU20120018A patent/CU20120018A7/es unknown
- 2012-01-30 CR CR20120052A patent/CR20120052A/es unknown
- 2012-01-30 ZA ZA2012/00716A patent/ZA201200716B/en unknown
- 2012-01-30 CL CL2012000238A patent/CL2012000238A1/es unknown
-
2013
- 2013-04-19 CU CU2013000057A patent/CU20130057A7/es unknown
- 2013-04-19 CU CU2013000058A patent/CU20130058A7/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013500726A5 (enExample) | ||
| JP2012001560A5 (enExample) | ||
| Harris et al. | Effect of pegylation on pharmaceuticals | |
| JP3177449B2 (ja) | 水溶性ポリマーで修飾したコンセンサスインターフェロン | |
| KR101309566B1 (ko) | 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법 | |
| JP2006523437A5 (enExample) | ||
| WO2005074546A2 (en) | Modified human growth hormone polypeptides and their uses | |
| JP2012532601A5 (enExample) | ||
| CN103068853A (zh) | 协同性生物分子-聚合物轭合物 | |
| JP2003519478A5 (enExample) | ||
| CA2682147A1 (en) | Modified fgf-21 polypeptides and their uses | |
| JP2010505444A5 (enExample) | ||
| CA2617064A1 (en) | Conjugates of a g-csf moiety and a polymer | |
| JP2006513992A5 (enExample) | ||
| JP2012504965A5 (enExample) | ||
| IL169165A (en) | Polymeric reagents and methods for the preparation thereof | |
| JP2008509889A5 (enExample) | ||
| JP2012505917A5 (enExample) | ||
| CN101495536B (zh) | 位点特异性聚乙二醇化的方法 | |
| JP2018515101A5 (enExample) | ||
| JP2007529539A5 (enExample) | ||
| CA2784800A1 (en) | Modified porcine somatotropin polypeptides and their uses | |
| EP2495258B1 (en) | Catechol polyethylene glycol derivative and protein or peptide conjugates, and method for preparing same | |
| CA2784793A1 (en) | Modified bovine somatotropin polypeptides and their uses | |
| JP2010524968A5 (enExample) |